XFOR Historical Cash Flow

XFOR Stock  USD 0.27  0.01  3.85%   
Analysis of X4 Pharmaceuticals cash flow over time is an excellent tool to project X4 Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Sale Purchase Of Stock of 0.0 or Stock Based Compensation of 4.7 M as it is a great indicator of X4 Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining X4 Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether X4 Pharmaceuticals is a good buy for the upcoming year.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.

About XFOR Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in XFOR balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which XFOR's non-liquid assets can be easily converted into cash.

X4 Pharmaceuticals Cash Flow Chart

At this time, X4 Pharmaceuticals' Sale Purchase Of Stock is relatively stable compared to the past year. As of 03/29/2025, Change In Working Capital is likely to grow to about 2.8 M, while Stock Based Compensation is likely to drop slightly above 4.7 M.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by X4 Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of X4 Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most accounts from X4 Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into X4 Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.At this time, X4 Pharmaceuticals' Sale Purchase Of Stock is relatively stable compared to the past year. As of 03/29/2025, Change In Working Capital is likely to grow to about 2.8 M, while Stock Based Compensation is likely to drop slightly above 4.7 M.

X4 Pharmaceuticals cash flow statement Correlations

0.71-0.120.01-0.31-0.23-0.450.1-0.1-0.4-0.060.430.21-0.2-0.070.08-0.4-0.19-0.190.09
0.71-0.390.30.12-0.51-0.460.42-0.340.13-0.040.37-0.16-0.13-0.11-0.07-0.54-0.25-0.250.41
-0.12-0.39-0.88-0.160.950.42-0.390.3-0.75-0.80.640.33-0.580.590.70.60.780.78-0.49
0.010.3-0.88-0.11-0.78-0.510.71-0.240.670.63-0.66-0.690.69-0.76-0.63-0.75-0.89-0.880.79
-0.310.12-0.16-0.11-0.210.5-0.34-0.420.520.12-0.040.19-0.270.51-0.290.510.360.35-0.3
-0.23-0.510.95-0.78-0.210.4-0.290.52-0.74-0.770.570.2-0.330.420.630.570.670.67-0.39
-0.45-0.460.42-0.510.50.4-0.540.180.07-0.15-0.020.38-0.330.390.280.720.650.65-0.57
0.10.42-0.390.71-0.34-0.29-0.540.00.25-0.09-0.07-0.920.41-0.67-0.09-0.71-0.55-0.540.99
-0.1-0.340.3-0.24-0.420.520.180.0-0.42-0.250.220.060.37-0.40.44-0.050.060.06-0.06
-0.40.13-0.750.670.52-0.740.070.25-0.420.62-0.71-0.360.33-0.31-0.55-0.21-0.37-0.370.33
-0.06-0.04-0.80.630.12-0.77-0.15-0.09-0.250.62-0.840.060.55-0.4-0.74-0.34-0.68-0.680.04
0.430.370.64-0.66-0.040.57-0.02-0.070.22-0.71-0.840.23-0.550.450.620.20.570.57-0.18
0.21-0.160.33-0.690.190.20.38-0.920.06-0.360.060.23-0.470.570.240.50.490.48-0.93
-0.2-0.13-0.580.69-0.27-0.33-0.330.410.370.330.55-0.55-0.47-0.79-0.58-0.55-0.81-0.810.49
-0.07-0.110.59-0.760.510.420.39-0.67-0.4-0.31-0.40.450.57-0.790.190.80.770.77-0.7
0.08-0.070.7-0.63-0.290.630.28-0.090.44-0.55-0.740.620.24-0.580.190.20.670.67-0.23
-0.4-0.540.6-0.750.510.570.72-0.71-0.05-0.21-0.340.20.5-0.550.80.20.810.81-0.73
-0.19-0.250.78-0.890.360.670.65-0.550.06-0.37-0.680.570.49-0.810.770.670.811.0-0.65
-0.19-0.250.78-0.880.350.670.65-0.540.06-0.37-0.680.570.48-0.810.770.670.811.0-0.64
0.090.41-0.490.79-0.3-0.39-0.570.99-0.060.330.04-0.18-0.930.49-0.7-0.23-0.73-0.65-0.64
Click cells to compare fundamentals

X4 Pharmaceuticals Account Relationship Matchups

X4 Pharmaceuticals cash flow statement Accounts

202020212022202320242025 (projected)
Sale Purchase Of Stock(1.1M)20.0M(277K)(2M)(12.0)0.0
Change In Cash(47.4M)2.4M39.9M(22.8M)(43.8M)(41.6M)
Stock Based Compensation5.4M6.2M5.2M8.7M8.2M4.7M
Free Cash Flow(60.2M)(71.5M)(77.2M)(96.6M)(131.2M)(124.7M)
Change In Working Capital(4.1M)(1.5M)5.7M344K2.7M2.8M
Begin Period Cash Flow128.1M80.7M83.1M123.0M100.2M67.9M
Other Cashflows From Financing Activities283K260K(4.6M)8.1M20.3M12.0M
Depreciation351K499K513K419K796K407.6K
Other Non Cash Items7.4M19.3M5.3M(4.8M)(102.5M)(97.3M)
Capital Expenditures1.4M615K103K60K326K325.5K
Total Cash From Operating Activities(58.8M)(70.9M)(77.1M)(96.5M)(130.9M)(124.4M)
Net Income(62.1M)(88.7M)(93.9M)(101.2M)(37.5M)(39.3M)
Total Cash From Financing Activities12.4M74.2M117.2M88.5M20.3M19.3M
End Period Cash Flow80.7M83.1M123.0M100.2M56.5M75.9M
Other Cashflows From Investing Activities(1.4M)(615K)4.8M98M112.7M118.3M
Investments(1.4M)(615K)(103K)(10.1M)67.0M70.3M
Net Borrowings3.5M481K12.4M(795K)(715.5K)(679.7K)
Change To Operating Activities(484K)(5.1M)(1.5M)5.7M6.6M6.9M
Change To Netincome7.2M6.5M19.3M6.2M7.1M6.9M
Change To Liabilities(2.8M)1.0M1.2M7.2M8.3M8.7M

Pair Trading with X4 Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with XFOR Stock

  0.8CDIOW Cardio DiagnosticsPairCorr
  0.7ELVN Enliven TherapeuticsPairCorr

Moving against XFOR Stock

  0.76LUCD Lucid DiagnosticsPairCorr
  0.74WM Waste ManagementPairCorr
  0.59GE GE AerospacePairCorr
  0.43PLX Protalix BiotherapeuticsPairCorr
  0.35PG Procter Gamble Sell-off TrendPairCorr
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for XFOR Stock Analysis

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.